134.63
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$136.21
Offen:
$136.1
24-Stunden-Volumen:
34,233
Relative Volume:
0.25
Marktkapitalisierung:
$2.60B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
53.64
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
-2.16%
1M Leistung:
+13.86%
6M Leistung:
+17.01%
1J Leistung:
+30.74%
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Vergleichen Sie LGND mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
LGND
Ligand Pharmaceuticals Inc
|
134.57 | 2.56B | 152.42M | 45.24M | 6.97M | 2.51 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
475.19 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
571.92 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
331.46 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
589.03 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.04 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-04-10 | Eingeleitet | Stifel | Buy |
2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-04-14 | Fortgesetzt | Stephens | Overweight |
2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
2020-10-06 | Eingeleitet | Barclays | Overweight |
2020-03-24 | Herabstufung | Argus | Buy → Hold |
2020-03-10 | Eingeleitet | Guggenheim | Neutral |
2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
2019-06-11 | Eingeleitet | Barclays | Equal Weight |
2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
2018-09-11 | Bestätigt | Argus | Buy |
2018-08-17 | Eingeleitet | Goldman | Neutral |
2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
2018-06-21 | Eingeleitet | Argus | Buy |
2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
2016-03-11 | Eingeleitet | Sidoti | Buy |
2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Mark Your Calendar: Ligand Q2 2025 Earnings Report Coming August 7Key Details Inside - Stock Titan
What analysts say about Ligand Pharmaceuticals Incorporated stockExceptional trading performance - Autocar Professional
Ligand Pharmaceuticals Incorporated Stock Analysis and ForecastFree Buy/Sell Signal Notifications - Autocar Professional
What drives Ligand Pharmaceuticals Incorporated stock priceRapid growth trajectories - jammulinksnews.com
Is Ligand Pharmaceuticals Incorporated a good long term investmentHigh-velocity capital appreciation - jammulinksnews.com
Is Ligand Pharmaceuticals Incorporated stock a growth or value playFree Capital Allocation Plans - beatles.ru
Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target - Investing.com Canada
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD - Investing.com Australia
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD By Investing.com - Investing.com Nigeria
What makes Ligand Pharmaceuticals Incorporated stock price move sharplyHigh Yield Opportunities - Newser
How Ligand Pharmaceuticals Incorporated stock performs during market volatilityFree Real-Time Trading Opportunities - Newser
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionFree Access to Community - Newser
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Announces Target Price $140 - 富途牛牛
Principal Financial Group Inc. Acquires 3,284 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus
Ligand Pharmaceuticals director Kozarich sells $116k in stock By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals director Kozarich sells $116k in stock - Investing.com Australia
Amalgamated Bank Has $564,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand earns $5 million milestone as partner launches molluscum treatment By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals (LGND) Soars 2.11% on ZELSUVMI Launch, Milestone Payment - AInvest
Pelthos Therapeutics shares rise 1.27% in after-hours after commercial launch of ZELSUVMI™ and merger with Channel Therapeutics. - AInvest
Pelthos, Ligand Gain After Launch Of First Prescription-At-Home Treatment For Water Warts - Stocktwits
ZELSUVMI's FDA Approval: A Breakthrough for Pelthos and a Windfall for Ligand? - AInvest
ZELSUVMI Launch Positions Ligand Pharmaceuticals for Growth in a Booming Skin Care Market - AInvest
Ligand earns $5 million milestone as partner launches molluscum treatment - Investing.com
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI - MarketScreener
Ligand Pharmaceuticals Partner Pelthos Launches Molluscum Contagiosum Treatment Zelsuvmi - MarketScreener
Ligand (LGND) Advances with Successful Launch of ZELSUVMI Gel | - GuruFocus
Ligand Pharmaceuticals Partner Pelthos Therapeutics Launches ZELSUVMI™ for Molluscum Contagiosum Treatment - Quiver Quantitative
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™ - GlobeNewswire
Breakthrough: First-Ever At-Home Treatment for Molluscum LaunchesLigand Secures $5M Milestone Payment - Stock Titan
GAMMA Investing LLC Has $62,000 Stock Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Receives Average Recommendation of “Buy” from Analysts - Defense World
Ligand’s LNHC concludes merger with CHRO - Yahoo Finance
Ligand Pharma Completes Merger Forming Pelthos Therapeutics - TipRanks
Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics - The Manila Times
Pelthos Therapeutics to Launch ZELSUVMI™ for Molluscum Contagiosum in July 2025 Following Merger with Ligand Pharmaceuticals - Quiver Quantitative
Ligand completes merger, Pelthos to launch molluscum treatment - Investing.com
Ligand completes merger, Pelthos to launch molluscum treatment By Investing.com - Investing.com UK
Ligand Pharmaceuticals Incorporated(NasdaqGM:LGND) added to Russell 2000 Growth-Defensive Index - MarketScreener
Ligand Pharmaceuticals: How a Biotech Royalty Model Drives Sustainable Growth - AInvest
Yousif Capital Management LLC Sells 181 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Handelsbanken Fonder AB Has $700,000 Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Wealth Enhancement Advisory Services LLC Takes $286,000 Position in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Cutaneous T-cell Lymphoma Market on Track for Major Expansion by 2034, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand Pharma - Barchart.com
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):